Meikang Biotechnology Co., Ltd.

Announcement on Repurchase and Cancellation of Restricted Stock Reduction and Creditor Notification

Legal Opinion on Meikang Biotechnology Co., Ltd.'s 2025 Annual Shareholders Meeting by Beijing Guofeng (Hangzhou) Law Firm

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Notice on the Holding of the 2025 Annual Shareholders Meeting

Legal Opinion on the Repurchase and Cancellation of the First Category Restricted Stock and Price Adjustment, and Invalidity of the Second Category Restricted Stock under the 2023 Incentive Plan of Meikang Biotechnology Co., Ltd.

Verification Opinions from the Board's Compensation and Assessment Committee on the Repurchase and Invalidity of Certain Restricted Stocks under the 2023 Incentive Plan

Announcement on the Invalidity of Part of the Second Category Restricted Stock Granted but Not Yet Vested under the 2023 Restricted Stock Incentive Plan

Announcement on the Repurchase and Cancellation of Part of the First Category Restricted Stock Granted but Not Yet Unlocked under the 2023 Restricted Stock Incentive Plan

Announcement on Adjusting the Repurchase Price of the First Category Restricted Stock Incentive Plan for 2023

2025 Annual Financial Settlement Report

2025 Annual Board Work Report

Announcement on the Renewal of the Accounting Firm for 2026

Announcement on the Company's 2026 Annual Compensation Plan for Directors and Senior Management

Shareholder Return Plan for the Next Three Years (2026-2028)

2025 Independent Director Work Report (Tian Yunpeng)

2025 Independent Director Work Report (Xu Ling)

Announcement on the Online Performance Presentation for the Year 2025

Internal Control Audit Report for the Year 2025

Self-Evaluation Report on Internal Control for the Year 2025

Compensation Management System for Directors and Senior Management (April 2026)

Announcement on the Holding Subsidiary Obtaining Medical Device Registration Certificate

Announcement on Changes in Accounting Policies

Announcement on the Provision for Asset Impairment and Write-off of Assets for the Year 2025

Announcement on Adjusting the Investment Variety of Idle Self-owned Funds in Entrusted Financial Management

Notice of the 2025 Annual Shareholders' Meeting

Announcement of the Resolution of the 19th Meeting of the 5th Board of Directors

Announcement on the Company's Profit Distribution Plan for the Year 2025

Quarterly Report for the First Quarter of 2026

Special Report on the Storage, Management, and Use of Raised Funds for the Year 2025

Special Verification Opinion by Zhongtian Guofu Securities Co., Ltd. on the Storage, Management, and Use of Raised Funds of Meikang Biotechnology Co., Ltd. for the Year 2025

Verification Report on the Special Report of the Storage, Management, and Use of Raised Funds for the Year 2025

Evaluation Report on the Performance of the Accounting Firm for the Year 2025

Report of the Board Audit Committee on the Evaluation of the Performance of the Accounting Firm for the Year 2025 and the Fulfillment of Supervisory Responsibilities